Huynh Tran Ngoc An, Wei Xinyi, Arulshankar Samiha, Huang James, Rajarubendra Nieroshan, Chu Kevin, Harper Matthew, Donnellan Scott, Ranasinghe Weranja
Department of Urology, Monash Health, Melbourne, Victoria 3806, Australia.
Department of Surgery, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria 3800, Australia.
Bladder (San Franc). 2025 Jun 4;12(3):e21200048. doi: 10.14440/bladder.2025.0006. eCollection 2025.
Upper tract urothelial carcinoma (UTUC) poses significant diagnostic challenges due to the limitations of current staging and grading techniques. Ureteroscopic (URS) biopsy is widely used preoperatively, but its accuracy, compared to final pathology, remains variable.
To evaluate the accuracy and limitations of URS biopsy in the staging and grading of UTUC, using final pathological results from radical nephroureterectomy (RNU) as the reference standard.
This retrospective study included 86 patients who underwent URS biopsy followed by RNU for UTUC at a tertiary institution between 2011 and 2023. Data were collected on patient demographics, tumor characteristics, imaging, and pathology results. The accuracy of URS biopsy in staging and grading was assessed, and its associations with pathological upstaging and non-diagnostic biopsies were statistically analyzed.
URS biopsy correctly staged 54.69% of tumors (κ = 0.311 [0.183 - 0.439], p<0.001) and correctly graded 70.93%. (κ = 0.447 [0.303 - 0.592], p<0.001). Pathological upstaging and upgrading occurred in 39.06% and 25.58% of cases, respectively. Non-diagnostic biopsies for both stage and grade were observed in 5.81% of cases, particularly in tumors located in the renal pelvis (p=0.0064). Complementary diagnostic tools, such as computed tomography urography (CTU) and urine cytology, showed limitations, with CTU detecting invasive disease in only 14.29% of cases and urine cytology identifying high-grade tumors in 11.11%.
URS biopsy demonstrates limitations in accurately staging and grading UTUC, resulting in a risk of both undertreatment and overtreatment. A multimodal diagnostic approach incorporating imaging, cytology, and clinical judgment is essential to optimizing management decisions and improving oncological outcomes.
由于当前分期和分级技术的局限性,上尿路尿路上皮癌(UTUC)带来了重大的诊断挑战。输尿管镜检查(URS)活检在术前被广泛应用,但其与最终病理结果相比的准确性仍存在差异。
以根治性肾输尿管切除术(RNU)的最终病理结果作为参考标准,评估URS活检在UTUC分期和分级中的准确性及局限性。
这项回顾性研究纳入了2011年至2023年间在一家三级医疗机构接受URS活检并随后进行RNU治疗UTUC的86例患者。收集了患者的人口统计学数据、肿瘤特征、影像学和病理结果。评估了URS活检在分期和分级中的准确性,并对其与病理分期上调和非诊断性活检的相关性进行了统计分析。
URS活检正确分期的肿瘤占54.69%(κ = 0.311 [0.183 - 0.439],p<0.001),正确分级的占70.93%(κ = 0.447 [0.303 - 0.592],p<0.001)。病理分期上调和分级上调分别发生在39.06%和25.58%的病例中。5.81%的病例观察到分期和分级的非诊断性活检,特别是位于肾盂的肿瘤(p = 0.0064)。计算机断层扫描尿路造影(CTU)和尿液细胞学等辅助诊断工具显示出局限性,CTU仅在14.29%的病例中检测到浸润性疾病,尿液细胞学在11.11%的病例中识别出高级别肿瘤。
URS活检在准确分期和分级UTUC方面存在局限性,导致治疗不足和过度治疗的风险。采用包括影像学、细胞学和临床判断的多模式诊断方法对于优化管理决策和改善肿瘤学结局至关重要。